First-line Afatinib in Patients with Non-small-cell Lung Cancer with Uncommon EGFR Mutations in South Korea

Mi Hyun Kim; Chang Min Choi; Sung Yong Lee; Cheol Kyu Park; Yoon Soo Chang; Kye Young Lee; Seung Joon Kim; Sei Hoon Yang; Jeong Seon Ryu; Jeong Eun Lee; Shin Yup Lee; Chan Kwon Park; Sang Hoon Lee; Seung Hun Jang; Seong Hoon Yoon; Tae Won Jang

doi:10.21873/anticanres.15636

First-line Afatinib in Patients with Non-small-cell Lung Cancer with Uncommon EGFR Mutations in South Korea

Mi Hyun Kim, Chang Min Choi, Sung Yong Lee, Cheol Kyu Park, Yoon Soo Chang, Kye Young Lee, Seung Joon Kim, Sei Hoon Yang, Jeong Seon Ryu, Jeong Eun Lee, Shin Yup Lee, Chan Kwon Park, Sang Hoon Lee, Seung Hun Jang, Seong Hoon Yoon, Tae Won Jang

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Background/Aim: Non-small cell lung cancers (NSCLCs) harboring uncommon epidermal growth factor receptor (EGFR) mutations are heterogeneous and show variable prevalence and clinical responses to EGFR tyrosine kinase inhibitors. We investigated the characteristics of uncommon EGFR mutations and the clinical efficacy of afatinib in patients with NSCLC harboring uncommon EGFR mutations. Patients and Methods: In this multicenter, retrospective study, we analyzed patients with NSCLC with uncommon EGFR mutations in 16 South Korean institutes.

Original language	English
Pages (from-to)	1615-1622
Number of pages	8
Journal	Anticancer Research
Volume	42
Issue number	3
DOIs	https://doi.org/10.21873/anticanres.15636
State	Published - Mar 2022

Bibliographical note

Publisher Copyright:
© 2022 International Institute of Anticancer Research. All rights reserved.

Keywords

Afatinib
Epidermal growth factor receptor
Lung neoplasms
Prognosis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/anticanres.15636

Cite this

Kim, M. H., Choi, C. M., Lee, S. Y., Park, C. K., Chang, Y. S., Lee, K. Y., Kim, S. J., Yang, S. H., Ryu, J. S., Lee, J. E., Lee, S. Y., Park, C. K., Lee, S. H., Jang, S. H., Yoon, S. H., & Jang, T. W. (2022). First-line Afatinib in Patients with Non-small-cell Lung Cancer with Uncommon EGFR Mutations in South Korea. Anticancer Research, 42(3), 1615-1622. https://doi.org/10.21873/anticanres.15636

@article{dc1bcf7783e647469235bcca027cb1cf,

title = "First-line Afatinib in Patients with Non-small-cell Lung Cancer with Uncommon EGFR Mutations in South Korea",

abstract = "Background/Aim: Non-small cell lung cancers (NSCLCs) harboring uncommon epidermal growth factor receptor (EGFR) mutations are heterogeneous and show variable prevalence and clinical responses to EGFR tyrosine kinase inhibitors. We investigated the characteristics of uncommon EGFR mutations and the clinical efficacy of afatinib in patients with NSCLC harboring uncommon EGFR mutations. Patients and Methods: In this multicenter, retrospective study, we analyzed patients with NSCLC with uncommon EGFR mutations in 16 South Korean institutes.",

keywords = "Afatinib, Epidermal growth factor receptor, Lung neoplasms, Prognosis",

author = "Kim, {Mi Hyun} and Choi, {Chang Min} and Lee, {Sung Yong} and Park, {Cheol Kyu} and Chang, {Yoon Soo} and Lee, {Kye Young} and Kim, {Seung Joon} and Yang, {Sei Hoon} and Ryu, {Jeong Seon} and Lee, {Jeong Eun} and Lee, {Shin Yup} and Park, {Chan Kwon} and Lee, {Sang Hoon} and Jang, {Seung Hun} and Yoon, {Seong Hoon} and Jang, {Tae Won}",

year = "2022",

month = mar,

doi = "10.21873/anticanres.15636",

language = "English",

volume = "42",

pages = "1615--1622",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "3",

}

TY - JOUR

T1 - First-line Afatinib in Patients with Non-small-cell Lung Cancer with Uncommon EGFR Mutations in South Korea

AU - Kim, Mi Hyun

AU - Choi, Chang Min

AU - Lee, Sung Yong

AU - Park, Cheol Kyu

AU - Chang, Yoon Soo

AU - Lee, Kye Young

AU - Kim, Seung Joon

AU - Yang, Sei Hoon

AU - Ryu, Jeong Seon

AU - Lee, Jeong Eun

AU - Lee, Shin Yup

AU - Park, Chan Kwon

AU - Lee, Sang Hoon

AU - Jang, Seung Hun

AU - Yoon, Seong Hoon

AU - Jang, Tae Won

PY - 2022/3

Y1 - 2022/3

N2 - Background/Aim: Non-small cell lung cancers (NSCLCs) harboring uncommon epidermal growth factor receptor (EGFR) mutations are heterogeneous and show variable prevalence and clinical responses to EGFR tyrosine kinase inhibitors. We investigated the characteristics of uncommon EGFR mutations and the clinical efficacy of afatinib in patients with NSCLC harboring uncommon EGFR mutations. Patients and Methods: In this multicenter, retrospective study, we analyzed patients with NSCLC with uncommon EGFR mutations in 16 South Korean institutes.

AB - Background/Aim: Non-small cell lung cancers (NSCLCs) harboring uncommon epidermal growth factor receptor (EGFR) mutations are heterogeneous and show variable prevalence and clinical responses to EGFR tyrosine kinase inhibitors. We investigated the characteristics of uncommon EGFR mutations and the clinical efficacy of afatinib in patients with NSCLC harboring uncommon EGFR mutations. Patients and Methods: In this multicenter, retrospective study, we analyzed patients with NSCLC with uncommon EGFR mutations in 16 South Korean institutes.

KW - Afatinib

KW - Epidermal growth factor receptor

KW - Lung neoplasms

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=85125564811&partnerID=8YFLogxK

U2 - 10.21873/anticanres.15636

DO - 10.21873/anticanres.15636

M3 - Article

C2 - 35220259

AN - SCOPUS:85125564811

SN - 0250-7005

VL - 42

SP - 1615

EP - 1622

JO - Anticancer Research

JF - Anticancer Research

IS - 3

ER -

First-line Afatinib in Patients with Non-small-cell Lung Cancer with Uncommon EGFR Mutations in South Korea

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this